Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  H. Lundbeck A/S    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Lundbeck boosted by stockpiling, launches key drug remotely

share with twitter share with LinkedIn share with facebook
05/12/2020 | 07:57am EDT

By Nikolaj Skydsgaard

Danish drugmaker Lundbeck beat first-quarter sales expectations on Tuesday as distributors and patients stocked up on medicines amid lockdowns to contain the coronavirus pandemic.

The company also said the U.S. launch of recently-acquired migraine drug eptinezumab, branded as Vyepti in the United States, had largely been a success, despite lockdowns forcing sales teams to switch from meetings with doctors to online contact.

"In a launch perspective, we've largely been as effective. But obviously, what hampers sales is that some hospitals and clinics have restrictions on letting patients in," chief financial officer Anders Goetzsche told Reuters.

Lundbeck, which specialises in treating mental disorders, joined rivals including AstraZeneca, GlaxoSmithKline and Novo Nordisk in benefitting from stockpiling of drugs as restrictions on movement were introduced across the world to tackle the coronavirus outbreak.

"Demand has been strong, but we also recognize that we have benefitted from patients gaining longer refill prescriptions as well as some stocking of products in many countries in response to the COVID-19 pandemic," Chief Executive Deborah Dunsire said in a statement.

The Copenhagen-based company posted quarterly sales of 4.56 billion Danish crowns (536.48 million pounds), above an average forecast of 4.34 billion in a Refinitiv Eikon poll of analysts, and an 8% increase from the same period last year.

Despite the strong first quarter, however, Lundbeck said it would maintain its full-year forecasts, with Goetzsche saying he expected sales would be affected by an unwinding of stockpiles in the second and third quarters.

Lundbeck shares topped the Copenhagen blue chip index in early morning trade, but were down 0.56% at 1036 GMT.

Sydbank analyst Soeren Loentoft Hansen linked the decline to the likely reversal of the stockpiling and to uncertainty over Vyepti's rate of take up in the United States.

Vyepti is the first migraine treatment of its kind, administered intravenously once every third month.

Lundbeck hopes it will eventually generate more than $1 billion in sales per year, but it will compete in a lucrative market with injectable treatments developed by rivals Eli Lilly, Amgen Inc and Teva.

The first patient was treated with Vyepti on April 6 and Goetzsche said negotiations with insurance planners were going as expected, adding several infusion centres and migraine experts had already bought Vyepti to treat patients.

Lundbeck expects to submit eptinezumab for regulatory approval in the European Union during 2020, and later in China and Japan.

(Reporting by Nikolaj Skydsgaard; Editing by Louise Heavens and Mark Potter)

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -1.04% 249.04 Delayed Quote.3.31%
ASTRAZENECA PLC 0.29% 8505 Delayed Quote.11.80%
H. LUNDBECK A/S -1.63% 242 Delayed Quote.-4.87%
NOVO NORDISK A/S -0.22% 431.85 Delayed Quote.11.69%
SWITCH, INC. -0.80% 18.7 Delayed Quote.26.18%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2.15% 3940 Delayed Quote.15.17%
THE NEW HOME COMPANY INC. 2.16% 3.31 Delayed Quote.-28.97%
WORLD CO., LTD. -5.40% 1420 End-of-day quote.-47.23%
share with twitter share with LinkedIn share with facebook
Latest news on H. LUNDBECK A/S
06/09H LUNDBECK A/S : Lundbeck plans to refocus and reinvigorate Research & Developme..
AQ
06/04Setback for Lundbeck as EU court adviser backs EU antitrust fine
RE
05/13H LUNDBECK A/S : Transactions with shares and linked securities in H. Lundbeck A..
AQ
05/12Lundbeck boosted by stockpiling, launches key drug remotely
RE
05/12H LUNDBECK A/S : Strong momentum across all strategic brands with 35% growth in ..
AQ
05/12H. LUNDBECK A/S : 1st quarter results
CO
05/07H. LUNDBECK A/S : quaterly earnings release
04/27H. LUNDBECK A/S : - High school students compete online in developing future med..
AQ
04/24H LUNDBECK A/S : High school students compete online in developing future medici..
AQ
03/30H LUNDBECK A/S : Lundbeck announces phase IIa study results of Lu AG06466 in adu..
AQ
More news
Financials
Sales 2020 17 851 M 2 708 M 2 708 M
Net income 2020 1 033 M 157 M 157 M
Net Debt 2020 3 787 M 574 M 574 M
P/E ratio 2020 41,9x
Yield 2020 0,97%
Capitalization 48 089 M 7 303 M 7 294 M
EV / Sales 2019
EV / Sales 2020 2,91x
Nbr of Employees 5 872
Free-Float 30,8%
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 260,73 DKK
Last Close Price 242,00 DKK
Spread / Highest target 38,0%
Spread / Average Target 7,74%
Spread / Lowest Target -17,4%
EPS Revisions
Managers
NameTitle
Deborah L. Dunsire President & Chief Executive Officer
Lars Søren Rasmussen Chairman
Anders Götzsche Chief Financial Officer, Director & Executive VP
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
H. LUNDBECK A/S-4.87%7 303
JOHNSON & JOHNSON-2.32%375 403
ROCHE HOLDING AG6.04%301 424
MERCK & CO., INC.-15.64%193 573
NOVARTIS AG-10.88%192 070
PFIZER, INC.-13.65%185 865